Bucloxic acid calcium salt

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 596410

CAS#: 32808-53-0

Description: Bucloxic acid calcium salt is an anti-inflammatory agent with analgesic & antipyretic properties.


Chemical Structure

img
Bucloxic acid calcium salt
CAS# 32808-53-0

Theoretical Analysis

MedKoo Cat#: 596410
Name: Bucloxic acid calcium salt
CAS#: 32808-53-0
Chemical Formula: C32H36CaCl2O6
Exact Mass: 626.15
Molecular Weight: 627.610
Elemental Analysis: C, 61.24; H, 5.78; Ca, 6.39; Cl, 11.30; O, 15.30

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 32808-51-8  

Synonym: Bucloxic acid calcium salt; CB 804 calcium; Calcium esfar; Bucloxic acid calcium;

IUPAC/Chemical Name: calcium 4-(3-chloro-4-cyclohexylphenyl)-4-oxobutanoate

InChi Key: FKJKZQUQHXSBHB-UHFFFAOYSA-L

InChi Code: InChI=1S/2C16H19ClO3.Ca/c2*17-14-10-12(15(18)8-9-16(19)20)6-7-13(14)11-4-2-1-3-5-11;/h2*6-7,10-11H,1-5,8-9H2,(H,19,20);/q;;+2/p-2

SMILES Code: O=C([O-])CCC(C1=CC=C(C2CCCCC2)C(Cl)=C1)=O.O=C([O-])CCC(C3=CC=C(C4CCCCC4)C(Cl)=C3)=O.[Ca+2]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 627.61 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Magous R, Bali JP, Escale R, Girard JP, Rechencq E, Rossi JC. Evidence for the existence of high affinity binding sites for indomethacin on human blood platelets. Mol Pharmacol. 1986 Jan;29(1):39-44. PubMed PMID: 3945226.

2: Paolaggi JB. [New non-steroidal anti-inflammatory agents]. Rev Prat. 1980 Apr 21;30(23):1525-30, 1533. French. PubMed PMID: 7189898.

3: Deidier CM, Schuhl JF. [Bucloxic acid in plastic surgery]. Ann Chir Plast. 1975;20(3-4):343-5. French. PubMed PMID: 1211844.

4: Lagrue G, Masbernard A, Giudicelli C, Hirbec G. Use of a new anti-inflammatory agent, bucloxic acid, in the treatment of chronic glomerular nephropathies. Arzneimittelforschung. 1974 Sep;24(9A SUPPL):1434-9. PubMed PMID: 4614821.

5: Mazué G, Vindel JA, Landsmann F, Brunaud M. Study of possible mutagenicity of bucloxic acid (804 CB). Arzneimittelforschung. 1974 Sep;24(9A SUPPL):1422-5. PubMed PMID: 4614818.

6: Mazué G, Landsmann F, Brunaud M. Study of possible teratogenicity of bucloxic acid (804 CB). Arzneimittelforschung. 1974 Sep;24(9A SUPPL):1413-22. PubMed PMID: 4480071.

7: Mazué G, Vallée E, Genet P, Navarro J, Brunaud M. Toxicological studies of bucloxic acid (804 CB). Arzneimittelforschung. 1974 Sep;24(9A SUPPL):1398-413. PubMed PMID: 4480070.

8: Chasseaud LF, Fry BJ, Gros PM. Metabolic and pharmacokinetic study of bucloxic acid. II. Pharmacokinetic study in the baboon. Arzneimittelforschung. 1974 Sep;24(9A SUPPL):1390-7. PubMed PMID: 4480069.

9: Gros PM, Davi HJ, Chasseaud LF, Hawkins DR. Metabolic and pharmacokinetic study of bucloxic acid. I. Isolation and identification of the main excretion products in animals and in man. Arzneimittelforschung. 1974 Sep;24(9A SUPPL):1385-90. PubMed PMID: 4480068.

10: Navarro J, Stoliaroff M, Savy JM, Berny C, Brunaud M. [Pharmacologic properties of a new, nonsteroidal anti-inflammatory agent, bucloxic acid (804 CB)]. Arzneimittelforschung. 1974 Sep;24(9A SUPPL):1368-78. French. PubMed PMID: 4480066.

11: Krausz F, Breliere JC, Vaillant J, Brunaud M, Navarro J. [A new nonsteroidal anti-inflammatory agent: bucloxic acid (804 CB)]. Arzneimittelforschung. 1974 Sep;24(9A SUPPL):1364-7. French. PubMed PMID: 4480065.

12: Brunard M. [Introduction: Esfar (bucloxic acid, 804 CB)]. Arzneimittelforschung. 1974 Sep;24(9A SUPPL):1359. French. PubMed PMID: 4480063.